H.C. Wainwright analyst Patrick Trucchio downgraded Freeline Therapeutics to Neutral from Buy with a price target of $6.50, down from $15, after the company entered into a definitive agreement under which Syncona is expected to acquire Freeline for $6.50 per share. The firm says the offering price is less than what it had believed FLT201 to be worth but views the transaction as the best path forward for further development of FLT201.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FRLN: